AKOUOS INC (AKUS) Stock Price & Overview
NASDAQ:AKUS • US00973J1016
Current stock price
The current stock price of AKUS is 13.29 USD. Today AKUS is up by 1.06%. In the past month the price increased by 1.22%. In the past year, price increased by 70.17%.
AKUS Key Statistics
- Market Cap
- 491.015M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.62
- Dividend Yield
- N/A
AKUS Stock Performance
AKUS Stock Chart
AKUS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to AKUS. When comparing the yearly performance of all stocks, AKUS is one of the better performing stocks in the market, outperforming 99.76% of all stocks.
AKUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AKUS. While AKUS has a great health rating, there are worries on its profitability.
AKUS Earnings
AKUS Forecast & Estimates
11 analysts have analysed AKUS and the average price target is 17.68 USD. This implies a price increase of 33.03% is expected in the next year compared to the current price of 13.29.
AKUS Groups
Sector & Classification
AKUS Financial Highlights
Over the last trailing twelve months AKUS reported a non-GAAP Earnings per Share(EPS) of -2.62. The EPS decreased by -20.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.06% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
AKUS Ownership
AKUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 368.574B | ||
| AMGN | AMGEN INC | 15.33 | 191.752B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 170.842B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 112.224B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.318B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.537B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.454B | ||
| BIIB | BIOGEN INC | 11.37 | 26.028B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.789B | ||
| MRNA | MODERNA INC | N/A | 21.305B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.501B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AKUS
Company Profile
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Company Info
IPO: 2020-06-26
AKOUOS INC
645 Summer Street, Suite 200
Boston MASSACHUSETTS 02210 US
CEO: Emmanuel Simons
Employees: 103
Phone: 18574101818.0
AKOUOS INC / AKUS FAQ
What does AKUS do?
Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The company is headquartered in Boston, Massachusetts and currently employs 103 full-time employees. The company went IPO on 2020-06-26. The firm is focused on developing precision therapies for forms of sensorineural hearing loss. The firm's genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus commonly used in gene therapy, known as adeno-associated virus (AAV), and a novel delivery approach. The firm is focused on executing its initiatives, which include the advancement of its lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of complex etiology, such as AK-antiVEGF for vestibular schwannoma; and development of internal manufacturing capabilities, and a commercial infrastructure.
Can you provide the latest stock price for AKOUOS INC?
The current stock price of AKUS is 13.29 USD. The price increased by 1.06% in the last trading session.
Does AKOUOS INC pay dividends?
AKUS does not pay a dividend.
How is the ChartMill rating for AKOUOS INC?
AKUS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists AKUS stock?
AKUS stock is listed on the Nasdaq exchange.
What is the employee count for AKUS stock?
AKOUOS INC (AKUS) currently has 103 employees.